14 results about "Tumor penetration" patented technology

The invention discloses a conical asymmetric nano robot for deep tumor penetration as well as a preparation method and application of the conical asymmetric nano robot. The structure of the asymmetric nano robot is Fe3O4 (at) mPDA (at) MnO2amp; mSiO2, and is marked as FPMamp; s; an FPMamp (Fabry Perot Module); the S nano-robot is nano-particles of an asymmetric structure, one end of the asymmetric structure is of a core-shell structure, the core is spherical Fe3O4, and the shell is mesoporous polydopamine particles; one end of the rod-like structure, which is far away from the Fe3O4, is conical; mnO2 is loaded on the surface of the mesoporous polydopamine; the asymmetric structure with the conical tail part is constructed, so that the forward wedging capability of the nano-robot in the moving process is improved, and the deep tumor penetrating performance is fundamentally improved; through the same nanorobot, collaborative treatment of multiple mechanisms of photo-thermal-Fenton-GSH depletion in space and time is achieved, the overall treatment efficiency of a deep tumor area is improved, and the problems that an existing asymmetric micro / nanorobot is insufficient in deep tumor penetrating capacity, the collaborative efficiency of a treatment module is limited and the like are solved.

The invention provides an application of M1 as an affinity of human source PD-L1 and / or mouse source PD-L1, and relates to the technical field of biological medicine. The invention proves that M1 can be used as a PD-L1 affinity for human / mouse cross reaction, and has low nanomole affinity for two targets. In cell-based function detection, M1 has similar affinity with mPDL1 and hPD-L1 expressed on the surface of a cell, and signal transduction is inhibited through a PD-L1: PD1 axis at a low micromolar concentration. The M1 disclosed by the invention can be used as a non-antibody treatment method to damage a PD-L1: PD1 signal channel, and the M1 shows high tumor permeability compared with an antibody, and particularly has a remarkable advantage in tumors (such as pancreatic tumors) with high fiber hyperplasia; the M1 shows selective uptake in the tumor for expressing the PD-L1.

The application relates to a carrier-free self-driven nanomotor and a preparation method and application thereof, and belongs to the technical field of biological medicines. The nanomotor is a nanometer assembly formed by co-assembly of a photothermal / light motion dual-enhanced photosensitizer and a near-infrared light response type nitric oxide donor BNN6 through intermolecular force, or is a nanometer assembly formed by co-assembly of a photothermal / light motion dual-enhanced photosensitizer and a near-infrared light response type nitric oxide donor BNN6 through intermolecular force and modified by a polyethylene glycol modifier. The application realizes a synergistic treatment mode of deep tumor penetration and high-efficiency killing by constructing a functional coupling system of "photothermal driving-NO release-motion enhancement-RNS cascade generation".

The application discloses a tumor-penetrating carrier-free nanomedicine as well as a preparation method and application thereof, and belongs to the field of nanomedicine. The carrier-free nanomedicine can significantly improve water solubility of a water-insoluble compound, has mitochondrion targeting and tumor active penetration capabilities, and under the action of a tertiary amine nitrogen oxygen group, the carrier-free nanomedicine can be mostly transported into mitochondria, which is beneficial to inducing a mitochondrion membrane potential drop and cell apoptosis. The carrier-free nanomedicine also has a good blood long-circulation effect and tumor accumulation capability in a body, and an antitumor effect is better than that of a clinical drug, and the carrier-free nanomedicine also has good biological safety. The preparation method is simple, and can be used for preparation of an antitumor drug.

The invention belongs to the technical field of biological medicine, and particularly relates to a nanometer drug delivery system with a tumor deep penetration effect and a preparation method and application of the nanometer drug delivery system. The polylactic acid-glycolic acid nano-particles are polylactic acid-glycolic acid copolymer nano-particles entrapped with chemotherapeutic drugs and carbon monoxide donors; the chemotherapeutic drug is monomethyl aurestatin E, and the carbon monoxide donor is S-nitroso-N-acetyl-DL-penicillamine; a lipid layer; the core is coated with the core; the targeting polypeptide is modified on the surface of the lipid layer; the targeting polypeptide is an R4F polypeptide; tumor cells are actively targeted through R4F polypeptide, the polylactic acid-glycolic acid copolymer nanoparticles wrapped by a lipid layer deeply penetrate into tumor tissues, nitric oxide is released through a carbon monoxide donor to degrade an extracellular matrix barrier, and deep penetration of loaded chemotherapeutic drugs and immune cells in the tumor tissues is synergistically promoted; the nano drug delivery system provided by the invention can be applied to preparation of drugs for treating solid tumors and delivery of drugs for targeting extracellular matrixes of the solid tumors.

The invention discloses an intelligent transdermal drug delivery system based on a tripterygium wilfordii exosome and a ferroptosis inducer as well as a preparation method and application of the intelligent transdermal drug delivery system, and belongs to the technical field of biological medicines. The method comprises the following steps: extracting tripterygium wilfordii exosomes (TExos) with natural anti-tumor activity, fusing the tripterygium wilfordii exosomes with a homologous tumor cell membrane by utilizing a repeated freeze-thaw method to construct a bionic targeting compound (CTE), and then loading RSL3 through a co-incubation method to form an R (at) CTE compound. The compound is further loaded into a porous microneedle through a 3D printing technology to prepare an R-(at) CTE-M transdermal drug delivery system. The drug delivery system constructed by the invention has excellent homologous targeting property and tumor penetrating ability, can effectively inhibit proliferation, migration and invasion of triple negative breast cancer cells, induce cell apoptosis and enhance cell ferroptosis, and shows a remarkable tumor inhibition effect and good biological safety in an animal model.

PSMA targeted metal chelate nanodrugs, methods of making these nanodrugs and methods of using them for radiodiagnosis and radiotherapy are provided.

This invention discloses a method for preparing and applying a chimeric peptide nanomedicine for photodynamic immunotherapy of triple-negative breast cancer. The nanomedicine uses the functional chimeric peptide Fmoc-K(PpIX)-PLGLAG-CVRARTR as its self-assembly core and is loaded with the exosomal PD-L1 inhibitor GW4869. This chimeric peptide contains an MMP-2 responsive sequence, the photosensitizer PpIX, and the PD-L1 targeting peptide CVRARTR. It is structurally stable in the bloodstream and can specifically accumulate in tumor tissues that highly express PD-L1 via the targeting peptide. Enzymatic degradation is triggered by the highly expressed MMP-2 in the tumor microenvironment, achieving structural deformation, controlled drug release, and enhanced deep tumor penetration. This invention can simultaneously achieve a triple synergistic therapeutic effect: PDT generates reactive oxygen species that directly kill tumor cells and trigger immunogenic cell death, enhancing immunogenicity; the targeting peptide competitively blocks PD-L1 on the cell surface, relieving local immunosuppression; and the inhibitor downregulates exosomal PD-L1 secretion, inhibiting systemic immune escape. This approach effectively overcomes the bottleneck of low response rates in existing TNBC immunotherapy.

The application provides a tumor microenvironment acid response deep penetration nanogel and application thereof. Specifically disclosed is an acid response nanogel carrier, wherein the nanogel carrier is obtained by polymerization of double-bonded hyaluronic acid, double-bonded cyclodextrin and 2,2-dimethyl acryloyl oxy-1-ethoxy propane under the action of a free radical polymerization initiator; the double-bonded hyaluronic acid is obtained by modification of hyaluronic acid with an acrylic anhydride compound; and the double-bonded cyclodextrin is obtained by modification of a cyclodextrin compound with an olefin acyl chloride compound. Further disclosed is an acid response nanogel loaded with an active ingredient, wherein the acid response nanogel carrier is used as an active ingredient carrier, and the active ingredient is included in the double-bonded cyclodextrin. The nanogel prepared by the application has good acid response performance and drug loading capacity, and has excellent tumor penetration capacity, which is beneficial to enhancing the anti-tumor effect of the drug or for detection.

The invention discloses a self-assembly aggregation-induced emission nanoprobe for targeted therapy and real-time imaging of non-small cell lung cancer and application, and belongs to the technical field of biological medicine. According to the invention, a self-assembled AIE compound with a structure of TPE-FFNPGYGKSLSRHDHIHHHPLGVR-PEG6 is firstly synthesized, the self-assembled AIE compound is self-assembled to form a self-assembled aggregation-induced emission nano-probe AIInps for targeting c-Met, and the AIInps has dual functions of realizing real-time imaging through fluorescence tracking, realizing targeted therapy by inhibiting the c-Met, realizing tumor specific accumulation and fluorescence tracking based on the design of the AIE, and realizing targeted treatment by inhibiting the c-Met. The AInps is a multifunctional NSCLC treatment platform, integrates targeted treatment and real-time imaging and has a very wide application prospect, and the limitation of poor tumor permeability and non-specific distribution in a traditional therapy method is overcome by the aid of the AInps, and the AInps is a multifunctional NSCLC treatment platform and integrates targeted treatment and real-time imaging.

The application discloses a self-assembled aggregation-induced emission nanoprobes for targeted therapy and real-time imaging of non-small cell lung cancer and application, and belongs to the technical field of biological medicine. The self-assembled aggregation-induced emission nanoprobes AIEnps are used for targeting c-Met, and the AIEnps have a dual function: one is to realize real-time imaging through fluorescence tracing, and the other is to realize targeted therapy by inhibiting c-Met. The design based on AIE realizes tumor-specific accumulation and fluorescence tracing, overcomes the limitations of poor tumor permeability and non-specific distribution in traditional therapy, and the AIEnps are a multifunctional NSCLC treatment platform, integrating targeted therapy and real-time imaging, and have a very broad application prospect.

This invention discloses a metal nanoparticle hybrid polymeric vesicle, its preparation method, and its applications. The method includes the following steps: adding a block copolymer solution to a metal salt aqueous solution via a syringe pump, i.e., preparing a preliminary hybrid vesicle by solvent exchange; dialyzing the obtained preliminary hybrid vesicle to remove unloaded metal ions; and adding an oxidizing agent or a reducing agent to the dialyzed preliminary hybrid vesicle to obtain the metal nanoparticle hybrid polymeric vesicle. This invention is simple to operate and highly reproducible. The prepared hybrid polymeric vesicle can act as a nanomotor during drug delivery, increasing tumor penetration under the driving force. After intracellular degradation, the metal nanoparticles can also act as nanozymes to produce therapeutic effects. This hybrid polymeric vesicle has excellent drug delivery capabilities and nanozyme characteristics, showing promising applications in drug delivery systems and the preparation of tumor therapeutic drugs.

This invention discloses a depolymerizable carbon dot composite system for enhancing tumor penetration, its preparation method, and its applications, belonging to the field of pharmaceutical technology. Specifically, it relates to the preparation of a carbon dot composite system for enhancing tumor penetration and its application in tumor cascade catalytic therapy and photothermal therapy. The carbon dot composite system consists of iron-doped red-light nanozyme carbon dots, glucose oxidase, and hyaluronic acid to reduce the system's immunogenicity. Through the targeted action of hyaluronic acid on the tumor site, depolymerization occurs in the tumor microenvironment under the influence of hyaluronidase and photothermal heating. Glucose oxidase consumes glucose at the tumor site to produce hydrogen peroxide, thereby generating more hydroxyl radicals and simultaneously performing starvation therapy. This invention's carbon dot composite system for enhancing tumor penetration combines cascade catalytic therapy, photothermal therapy, and starvation therapy to achieve highly efficient tumor growth inhibition, providing an important reference for multimodal tumor treatment.

This invention relates to Furin / hydroxyl radical dual-responsive size-changing nanoparticles, their preparation, and applications. The Furin / hydroxyl radical dual-responsive size-changing nanoparticles use an AIE photosensitizer as the core and DSPE-PEG as the substrate. 2K MAL nanoparticles serve as carriers, with functional peptides coupled to their surfaces via Michael addition reactions. The core functional building block is a self-designed and custom-synthesized R1 peptide, which possesses a triple function: high specificity recognition by Furin protease, OH-responsive tyrosine oxidation cross-linking, and coupling with DSPE-PEG nanoparticles. Its simple sequence significantly enhances tumor selectivity. The peptide is covalently modified with natural peptides using a nanoprecipitation method, avoiding complex chemical modifications and exogenous orthogonal biological groups, thus mitigating the toxicity and synthesis costs of traditional systems. Under the dual conditions of Furin protease overexpression and the presence of OH, size transformation is triggered, enabling deep tumor penetration with small sizes and long-term intratumoral retention through in-situ large-size assembly, demonstrating clinical translational potential.